• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mirati Therapeutics Inc.

    1/31/24 2:08:26 PM ET
    $MRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRTX alert in real time by email
    SC 13G 1 us60468t1051_013124.txt us60468t1051_013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Mirati Therapeutics Inc -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 60468T105 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 60468T105 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 3680503 (6) Shared voting power 0 (7) Sole dispositive power 3866202 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 3866202 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 5.5% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Mirati Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 3545 CRAY COURT SAN DIEGO CA 92121 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 3866202 Percent of class 5.5% Number of shares as to which such person has: Sole power to vote or to direct the vote 3680503 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 3866202 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Mirati Therapeutics Inc. No one person's interest in the common stock of Mirati Therapeutics Inc is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 31, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Life Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock (Luxembourg) S.A. BlackRock Investment Management (Australia) Limited BlackRock Advisors (UK) Limited BlackRock Fund Advisors BlackRock Fund Managers Ltd *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $MRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$51.00 → $48.00Neutral → Buy
    Citigroup
    8/9/2023$45.00Neutral → Buy
    B. Riley Securities
    8/9/2023$45.00Overweight
    Piper Sandler
    7/27/2023Sector Underperform
    Scotiabank
    5/25/2023Perform → Outperform
    Oppenheimer
    12/14/2022Hold
    Needham
    12/9/2022$121.00 → $53.00Buy → Neutral
    Citigroup
    12/8/2022$110.00 → $59.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $MRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mirati Therapeutics Inc.

      SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 4:21:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 2:51:56 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 9:13:21 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Financials

    Live finance-specific insights

    See more
    • Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

      Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum, M.D., Ph.D., President and Founder, to assume role of interim CEO during search for permanent CEO Company will announce financial results for the second quarter 2023 along with recent corporate updates during a conference call at 5:30 p.m. ET / 2:30 p.m. PT SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASD

      8/8/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

      SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 6674271. A replay of the call will be available approximately 2 hours after

      7/25/23 4:30:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

      SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In add

      5/9/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KRAZATI issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/14/22 7:40:10 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/12/22 6:09:02 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy

      12/12/22 4:56:01 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

      SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ

      1/10/24 8:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

      SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati

      11/2/23 7:30:00 AM ET
      $KURA
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

      Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh

      10/8/23 5:16:00 PM ET
      $BMY
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Mirati Therapeutics Inc.

      15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)

      2/2/24 4:05:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:14 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:09 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mirati Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously

      8/10/23 7:25:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00

      8/9/23 8:29:32 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Mirati Therapeutics with a new price target

      Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00

      8/9/23 7:36:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Boxer Capital, Llc returned 6,859,544 shares to the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/25/24 4:32:24 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cherrington Julie M returned 11,252 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:07 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharp Shalini returned 16,222 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:09 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

      SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer." Dr. Gallagher has over 30 years of strategic, commercial, business development and drug dev

      6/23/23 4:00:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

      Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pr

      11/8/22 4:05:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

      - Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine. Prior to Medikine, he was Executive Vice President a

      10/4/22 4:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care